Search Results

You are looking at 171 - 180 of 403 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Novel Systemic Therapies for Small Cell Lung Cancer

Charles M. Rudin, Christine L. Hann, Craig D. Peacock, and D. Neil Watkins

carcinoma (SCLC): the angiogenic phenomenon . Eur J Cardiothorac Surg 2002 ; 21 : 1105 – 1110 . 34. Sandler A Szwaric S Dowlati A . A phase II study of cisplatin plus etoposide plus bevacizumab for previously untreated extensive stage small

Full access

Systemic Therapy for Advanced Pancreatic Neuroendocrine Tumors: An Update

Diane L. Reidy-Lagunes

with a fluorouracil, oxaliplatin, and bevacizumab combination. The first by Bergsland et al. 37 reported a 50% response rate in 12 patients with progressive pancNETs who received short-term infusional 5-fluorouracil plus leucovorin (FOLFOX) and

Full access

Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes

Michael S. Lee, David G. Menter, and Scott Kopetz

Consensus Molecular Subtypes Primary CRC site is prognostic but not predictive of outcome with bevacizumab-based therapy. An analysis of 2 prospective randomized controlled trials of chemotherapy with or without bevacizumab found that a statistical

Full access

NCCN Evidence Blocks

Robert W. Carlson and Eric Jonasch

agents are available for the adjuvant treatment of resected primary RCC, multiple agents are available for metastatic disease, including the antiangiogenic agents sunitinib, pazopanib, bevacizumab/interferon, sorafenib, axitinib, and recently approved

Full access

Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer

Min Huang, Joyce O’Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortes, Scott Ramsey, Andrew Briggs, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, and Peter A. Fasching

focused on patients with TNBC, whereas the other RCTs included patients with any or broader BC subtypes (eg, HER2-negative) but reported TNBC-specific results. A variety of investigational neoadjuvant interventions were evaluated, including bevacizumab in

Full access

Routine Imaging or No Routine Imaging, Is That the Question?

Laurie Elit, Gregory R. Pond, and Mark N. Levine

group of only 4 providers. Further, during the 16-year period of this study, practice patterns would likely have changed substantially due to the introduction of PARP inhibitors or bevacizumab. The study included no data on whether patients receiving

Full access

NCCN Guidelines Insights: Hepatobiliary Cancers, Version 2.2019

Featured Updates to the NCCN Guidelines

Al B. Benson III, Michael I. D’Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Daniel Brown, Daniel T. Chang, Jordan Cloyd, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andreas Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey Schefter, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Lydia J. Hammond, and Susan D. Darlow

(doxorubicin) led to less consensus among the panel. Bevacizumab, another VEGF receptor inhibitor, has modest clinical activity (as a single agent or in combination with other systemic therapy options) in phase II studies in patients with advanced HCC. 39 – 43

Full access

Accelerated Approval Program Versus NCCN Guidelines as Mechanisms for Early Drug Access

Austin Wesevich and Mark J. Ratain

5 years after the AA date, although more recent withdrawals have been within 3 years of AA. One concern is that prior AA indications persist in NCCN Guidelines despite unsuccessful confirmatory trials. 12 For example, bevacizumab received AA on

Full access

Non–Small Cell Lung Cancer

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Apar Kishor P. Ganti, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, Mohammad Jahanzeb, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, George R. Simon, Scott J. Swanson, Douglas E. Wood, and Stephen C. Yang

whom the standard premedications (i.e., dexamethasone, H2 blockers, H1 blockers) are contraindicated. 212 , 213 Specific targeted therapies have been developed for treating advanced lung cancer. 214 , 215 Bevacizumab is a recombinant monoclonal

Full access

Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?

Virginia G. Kaklamani and William J. Gradishar

phase II clinical trial evaluating the role of bevacizumab and carboplatin in TNBC. The trial had a 2 x 2 factorial design. Patients received preoperative chemotherapy with paclitaxel, 80 mg/m 2 weekly for 12 weeks followed by AC for 4 cycles. Patients